BCLI earnings analysis
What we found in BCLI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing highlights severe financing and execution risk rather than operating growth: no revenue, margin or free-cash-flow data were disclosed, and diluted loss per share was $(0.35) versus $(0.34) in the prior-year quarter. Liquidity was approximately $0.2 million, while the company issued additional notes with combined principal of $266,800 after quarter-end and disclosed a material weakness in short-term-loan controls as of June 30, 2026. Preparations for the planned 200-patient ENDURANCE trial and approximately $2.4 million of first-half financing are constructive, but litigation claims of approximately $0.5 million and $0.7 million add to the downside risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- H1 financing supports ENDURANCE preparation
- The company raised approximately $2.4 million during the first half of 2026, including two May private placements of $200,000 each, supporting preparations for the planned 200-patient ENDURANCE trial.
- ENDURANCE trial preparation advances
- Management is preparing the Phase 3b ENDURANCE trial, which is planned to enroll approximately 200 ALS patients.
- May offerings include warrant upside
- The May 11 and May 19 offerings each included warrants to purchase 1.2 shares per underlying share at an exercise price of $1.45 per share, potentially providing additional future financing if exercised.
- Post-quarter notes provide $221,500 cash
- The company obtained $96,500 of cash proceeds from the July 2 note and $125,000 from the July 6 note, for total stated cash proceeds of $221,500 after original issue discounts.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness in loan controls
- Management concluded disclosure controls were not effective as of June 30, 2026 because of a material weakness in controls over the initiation, review, authorization and execution of short-term loans. The weakness creates a reasonable possibility that a material misstatement could not be prevented or detected timely.
- Limited liquidity and rising debt burden
- Liquidity remains severely constrained, with approximately $0.2 million of liquidity noted in the prior quarterly disclosure, while the company is relying on additional debt financing. The July 2 and July 6 notes carry principal amounts of $115,000 and $151,800, respectively, and require scheduled amortization payments.
- Material litigation exposure
- Two material legal claims remain pending: 3D Communications seeks approximately $0.5 million in unpaid invoices, and Sourasky University Medical Center seeks NIS 2,117,950, approximately $0.7 million, for alleged unpaid clean-room fees.
- Limited analyst coverage and market access
- The company added a risk that its OTCQB-listed common stock may receive limited analyst coverage because it is not traded on a national securities exchange, potentially reducing investor visibility and liquidity.
- Macroeconomic funding risk
- The company added exposure to macroeconomic and financial-market disruption, including inflation, interest rates, tariffs and financial-institution liquidity events, which could impair its ability to raise funding on acceptable terms.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.35
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management discussed preparations for the planned ENDURANCE Phase 3b trial, expected to enroll approximately 200 ALS patients.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- BrainStorm Cell Therapeutics (BCLI) reported a quarterly net loss of $2,127,000 for Q1 2026, an improvement from a loss of $2,864,000 in Q1 2025. The company continues to operate as a development-stage entity with no…
- 10-K · March 31, 2026
- BrainStorm (BCLI) remains a development-stage, pre-revenue cell therapy company focused on commercializing its NurOwn® autologous MSC platform for ALS and other neurodegenerative diseases. The company secured an SPA…
- 10-Q · November 14, 2025
- BrainStorm (BCLI) remains a pre-revenue clinical-stage company. Q3 2025 showed an improved per‑share loss (‑$0.19) and lower operating loss versus year-ago, but the company faces acute liquidity pressure with cash and…
- 10-Q · August 14, 2025
- BrainStorm (BCLI) remains a pre-revenue clinical-stage company: no product revenue is reported and the company reported a net loss of $2,903 for the quarter and $(0.34) basic and diluted EPS. Liquidity improved modestly…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCLI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever